MedTrace Logo

Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis

NCT02943057 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-05-18

No results posted yet for this study

Summary

25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for 6 weeks.

Following 6 weeks of continuous application of 2% guttae ganciclovir, patient will be reviewed at the clinic within 3 hours following the last application of topical ganciclovir and clinical features will be documented for activity assessment. An aqueous sample 0.2ml is drawn. 0.1ml will be sent for RT-PCR for CMV viral load and another 0.1ml will be sent for ganciclovir drug level by HPLC method.

Conditions

  • Cytomegalovirus Infections

Interventions

DRUG

2% guttae ganciclovir

2% guttae ganciclovir 5 times a day for 6 weeks

Sponsors & Collaborators

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • SP Chee · Singapre national eye centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2024-01-31
Completion
2024-11-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943057 on ClinicalTrials.gov